Literature DB >> 24846794

High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.

Li-Fu Kuo1, Chuan-Mo Lee, Chao-Hung Hung, Jing-Houng Wang, Tsung-Hui Hu, Sheng-Nan Lu, Chi-Sin Changchien, Chien-Hung Chen.   

Abstract

BACKGROUND: A recent study showed that chronic hepatitis B virus (HBV) carriers with nucleos(t)ide analogue (NA)-induced hepatitis B antigen (HBeAg) seroconversion occurring before the age of 30 years have a higher risk of HBV reactivation. AIM: To compare the risk of HBV reactivation and HBeAg seroreversion between patients with spontaneous and NA-induced HBeAg seroconversion.
METHODS: A total of 135 and 251 non-cirrhotic patients with NA-induced and spontaneous HBeAg seroconversion, respectively, were analyzed.
RESULTS: NA-induced HBeAg seroconverters faced higher risks of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconverters (P < 0.001). In spontaneous HBeAg seroconverters, age at HBeAg seroconversion, sex, HBV DNA levels before HBeAg seroconversion, HBV genotype C, and pre-S deletions were independent predictors of HBV reactivation. In NA-induced HBeAg seroconverters, only age at baseline was an independent predictor of HBV reactivation. To determine whether the difference in the incidence of HBV reactivation or HBeAg seroreversion between two groups was age-specific, we analyzed these patients according to their age at HBeAg seroconversion (20-29, 30-39, and ≥40 years). Our data showed that NA-induced HBeAg seroconversion was an independent predictor of HBV reactivation and HBeAg seroreversion than spontaneous HBeAg seroconversion in patients older than 40 years at HBeAg seroconversion, but not in patients between 20-29 and 30-39 years of age.
CONCLUSIONS: NA-induced HBeAg seroconverters are associated with higher risks of HBV reactivation and HBeAg seroreversion compared to spontaneous HBeAg seroconverters, especially in patients who are older than 40 years at HBeAg seroconversion.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24846794     DOI: 10.1007/s10620-014-3194-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

Review 1.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

2.  Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection.

Authors:  C M Lee; S N Lu; C S Changchien; C T Yeh; T T Hsu; J H Tang; J H Wang; D Y Lin; C L Chen; W J Chen
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

3.  Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

Authors:  Ting-Tsung Chang; Yun-Fan Liaw; Shun-Sheng Wu; Eugene Schiff; Kwang-Hyub Han; Ching-Lung Lai; Rifaat Safadi; Samuel S Lee; Waldemar Halota; Zachary Goodman; Yun-Chan Chi; Hui Zhang; Robert Hindes; Uchenna Iloeje; Suzanne Beebe; Bruce Kreter
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

4.  Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.

Authors:  B C Song; D J Suh; H C Lee; Y H Chung; Y S Lee
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

5.  Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Jing-Houng Wang; Tsung-Hui Hu; Chao-Hung Hung; Chi-Sin Changchien; Sheng-Nan Lu
Journal:  Hepatol Int       Date:  2012-06-21       Impact factor: 6.047

6.  Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan.

Authors:  C M Lee; C H Chen; S N Lu; H D Tung; W J Chou; J H Wang; T M Chen; C H Hung; C C Huang; W J Chen
Journal:  Scand J Gastroenterol       Date:  2003-01       Impact factor: 2.423

Review 7.  Global control of hepatitis B virus infection.

Authors:  Jia-Horng Kao; Ding-Shinn Chen
Journal:  Lancet Infect Dis       Date:  2002-07       Impact factor: 25.071

8.  Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B.

Authors:  Hyun Woong Lee; Heon Ju Lee; Jae Seok Hwang; Joo Hyun Sohn; Jae Young Jang; Ki Jun Han; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Yong Han Paik; Chun Kyon Lee; Kwan Sik Lee; Chae Yoon Chon; Kwang-Hyub Han
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

9.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

10.  Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion.

Authors:  Yuan-Hung Kuo; Chien-Hung Chen; Jing-Houng Wang; Chou-Hung Hung; Po-Lin Tseng; Sheng-Nan Lu; Chi-Sin Changchien; Chuan-Mo Lee
Journal:  Scand J Gastroenterol       Date:  2010       Impact factor: 2.423

View more
  4 in total

Review 1.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

2.  Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.

Authors:  Tse-Ling Fong; Andy Tien; Kahee J Jo; Danny Chu; Eddie Cheung; Edward A Mena; Quang-Quoc Phan; Andy S Yu; Wafa Mohammed; Andrew Velasco; Vinh-Huy LeDuc; Nickolas Nguyen; Steven-Bui Han; Mimi Chang; Ho S Bae; Yong-Won Cho; Myron J Tong; Stewart L Cooper
Journal:  Dig Dis Sci       Date:  2015-07-03       Impact factor: 3.199

Review 3.  An update of biochemical markers of hepatocellular carcinoma.

Authors:  Abdulaziz Ajlan M AlSalloom
Journal:  Int J Health Sci (Qassim)       Date:  2016-01

4.  Association of Hepatitis B Virus DNA Level and Follow-up Interval With Hepatocellular Carcinoma Recurrence.

Authors:  Wei Wang; Shilin-L Tian; Hui Wang; Chun-Chun Shao; Yong-Zheng Wang; Yu-Liang Li
Journal:  JAMA Netw Open       Date:  2020-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.